🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First National Immunotoxity Board today! We learned a lot from sharing experience on organ transplant patients, severe neurotoxicity and reumatological toxicity. Next meeting in 15th of March 4pm. Check lnkd.in/dh96Mv8. #immunotherapy #immunotoxicity #BSMO #UZBrussel

Immune-related adverse events (irAEs) can occur more than 1 year after starting anti-PD1 therapy. This manuscript describes the characteristics and course of delayed irAEs in a series of 118 patients treated for melanoma annalsofoncology.org/article/S0923-… Professor Georgina Long AO (Bluesky @gvlongphdmd) Sandrine Aspeslagh

Almost ready for this virtual meeting on the management of adverse events during immunotherapy combination treatment (IO+IO - IO+antiVEGF - IO+chemo). Case based discussions! Join us at 7pm CEST 🌍 🔜 cutt.ly/ynu3WeF Sandrine Aspeslagh #immunotox #irAE

Nog meer onderzoeksnieuws! Sandrine Aspeslagh en collega's zullen een plant-gebaseerd dieet implementeren bij onco-patiënten die immuuntherapie krijgen om te evalueren of de toxiciteit zo kan worden gereduceerd #FORX

🔎GEZOCHT: gemotiveerde collega (basis)arts met een ❤️ voor klinisch onderzoek om ons team digestieve oncologie te versterken. Bouw mee aan de innovatieve kankerzorg van morgen! UZ Leuven w.rfer.us/UZLEUVENegX3TH - RT = 👍

UZ Brussel Sandrine Aspeslagh Getting to the #root of it! 🍏🥬🥕🍇 uzbrusselfoundation.be/forx

Double strand DNA breaks (DSBs) enhance PD-L1 expression through ATM/ATR/Chk1 & this is accentuated by BRCA2 loss nature.com/articles/s4146… Preclinical rationale for checkpoint inhibitors in BRCA2 mutant cancers #PancreaticCancer Nature Communications

Bonjour Twitter – nous partageons de l’information médicale claire, précise et expertisée sur le traitement des #cancers, et proposons des formations à destination des professionnels de santé NetCancer buff.ly/2n5hYpM

Scientists at @MedImmune have found that a mutant protein linked to #cancer can be neutralized. Read more: bit.ly/2hMwBbY. nature.com/articles/ncomm… @nature

Cancer #ImmunoTherapy | TransDermal #Patch delivery of #TumorAntigens | ZhenGu UNC-Chapel Hill Science Immunology buff.ly/2n6dVJT

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria ejcancer.com/article/S0959-…

Modernizing Clinical Trial Eligibility: Recommendations of ASCO Friends of Cancer Research Minimum Age Working Group ow.ly/v0EP30fry0I

Phase II study of BGJ398 (a pan-FGFR kinase inhibitor) in FGFR-altered advanced cholangiocarcinoma bit.ly/2Biawtz

Dr. Sosman: Is this for real? All the I-O therapy trials in oncology! What are side-effects of I-O combinations? Stay tuned #OCECardioOnc17 @gulleyj1 FDA Oncology Laleh Amiri-Kordestani, MD @northwestern Lurie Cancer Center

#Pathologists Must read review on the tumor immune microenvironment for staging & therapeutics By two of my favorite Johns Hopkins Pathology faculty stars Ashley Cimino-Mathews & Janis Taube nature.com/articles/modpa… Someday immune parameter assessment will be part of TNM classification

Christine Desmedt from the Breast Cancer Translational Lab at Institut Jules Bordet Instituut presenting an overview on fundamental #PrecisionMedicine research in #BreastCancer at the Belgian Society of Senology Conference #bcsm

Philippe Aftimos, MD  from Institut Jules Bordet Instituut giving a very instructive talk about #PrecisionMedicine in the treatment of #BreastCancer at the Belgian Society of Senology Conference #bcsm seno.be/files/20171202…

Proud of our fellows prizes at the annual BAU Posters contest Université libre de Bruxelles UZ Leuven Institut Jules Bordet Instituut steven joniau Simone Albisinni Nieves Romain Diamand #cancer

"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors" beware of these ones! They can be insidious —a glimpse of our experience with Dana-Farber Brigham and Women's Hospital colleagues ncbi.nlm.nih.gov/pubmed/2919137…

Happy to see the development of novel endocrine therapies, here a selective estrogen receptor covalent antagonist. We could cure more patients with ER+ #BreastCancer if they successfully advance to the adjuvant setting #SABCS17 #bcsm cancerres.aacrjournals.org/content/77/13_…